Literature DB >> 1616350

Inhibition of astrocyte proliferation and binding to brain tissue of anticardiolipin antibodies purified from lupus serum.

K H Sun1, W T Liu, C Y Tsai, T S Liao, W M Lin, C L Yu.   

Abstract

Polyclonal anticardiolipin antibodies purified from pooled serum samples of patients with systemic lupus erythematosus were shown to have inhibitory effects on cultured normal rat brain astrocytes (RBA-1 cells). Anticardiolipin antibodies at concentrations from 50 to 200 micrograms/ml inhibited the [3H]thymidine incorporation of RBA-1 cells in a dose dependent manner after three days of culture. A kinetic study showed that anticardiolipin antibodies (100 micrograms/ml) maximally inhibit the proliferation of RBA-1 cells (20.6 (5.1)% of the control value) after incubation for one day. In contrast, human gamma globulin (100 micrograms/ml) had no effect on these cells. In the presence of anticardiolipin antibodies (100 micrograms/ml), the RBA-1 cells attached to the bottom of wells became spherical and the expression of glial fibrillary acidic protein in the cytoplasm was slightly reduced. Using 3,3'-dihexyloxacarbocyanine iodide as an indicator, anticardiolipin antibodies depolarised the membrane potential of RBA-1 cells after one day of culture. In addition, the percentage binding of RBA-1 cells with anticardiolipin antibodies was greater than with gamma globulin as determined by flow cytometric analysis. Immunofluorescence staining of brain tissue from BALB/c mice with anticardiolipin antibodies was noted in the corpus callosum, the cellular zone near the corpus callosum, and cells scattered in brain tissue. These results suggest that anticardiolipin antibodies have an inhibitory effect on brain cells and elicit thrombus formation in brain vessels, which plays a part in neuropsychiatric lupus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1616350      PMCID: PMC1004730          DOI: 10.1136/ard.51.6.707

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  33 in total

1.  Cerebral infarct, TIA, and lupus inhibitor.

Authors:  M Fisher; W McGehee
Journal:  Neurology       Date:  1986-09       Impact factor: 9.910

Review 2.  The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies.

Authors:  S R Levine; K M Welch
Journal:  Arch Neurol       Date:  1987-08

Review 3.  Astrocytes: auxiliary cells for immune responses in the central nervous system?

Authors:  L Hertz; D E McFarlin; B H Waksman
Journal:  Immunol Today       Date:  1990-08

4.  Cerebrospinal fluid anti-cardiolipin antibodies in neurological diseases.

Authors:  F Lolli; S Matá; M C Baruffi; L Amaducci
Journal:  Clin Immunol Immunopathol       Date:  1991-05

5.  Cerebrovascular ischemia associated with lupus anticoagulant.

Authors:  S R Levine; K M Welch
Journal:  Stroke       Date:  1987 Jan-Feb       Impact factor: 7.914

6.  Magnetic resonance imaging of central nervous system lesions in patients with lupus erythematosus. Correlation with clinical remission and antineurofilament and anticardiolipin antibody titers.

Authors:  C L Bell; C Partington; M Robbins; F Graziano; P Turski; S Kornguth
Journal:  Arthritis Rheum       Date:  1991-04

7.  Inhibitory effects of anticardiolipin antibodies on lymphocyte proliferation and neutrophil phagocytosis.

Authors:  C L Yu; K H Sun; C Y Tsai; S R Wang
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

8.  Neurological disease associated with antiphospholipid antibodies.

Authors:  D P Briley; B M Coull; S H Goodnight
Journal:  Ann Neurol       Date:  1989-03       Impact factor: 10.422

9.  Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome.

Authors:  R A Asherson; M A Khamashta; A Gil; J J Vazquez; O Chan; E Baguley; G R Hughes
Journal:  Am J Med       Date:  1989-04       Impact factor: 4.965

10.  Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus.

Authors:  H G Bluestein; G W Williams; A D Steinberg
Journal:  Am J Med       Date:  1981-02       Impact factor: 4.965

View more
  10 in total

1.  Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome.

Authors:  I Krause; S Lev; A Fraser; M Blank; M Lorber; L Stojanovich; J Rovensky; J Chapman; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2005-03-18       Impact factor: 19.103

2.  Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model.

Authors:  L Ziporen; Y Shoenfeld; Y Levy; A D Korczyn
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

3.  Diffusion tensor imaging in patients with obstetric antiphospholipid syndrome without neuropsychiatric symptoms.

Authors:  Fabricio R Pereira; Francesco Macri; Marcel P Jackowski; William J Kostis; Jean-Christophe Gris; Jean-Paul Beregi; Choukri Mekkaoui
Journal:  Eur Radiol       Date:  2015-07-23       Impact factor: 5.315

Review 4.  Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview.

Authors:  Penka A Atanassova
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

5.  Increased anti-phospholipid antibodies in autism spectrum disorders.

Authors:  Milo Careaga; Robin L Hansen; Irva Hertz-Piccotto; Judy Van de Water; Paul Ashwood
Journal:  Mediators Inflamm       Date:  2013-09-23       Impact factor: 4.711

Review 6.  Neuroantibody biomarkers: links and challenges in environmental neurodegeneration and autoimmunity.

Authors:  Hassan A N El-Fawal
Journal:  Autoimmune Dis       Date:  2014-06-23

Review 7.  Clearance Deficiency and Cell Death Pathways: A Model for the Pathogenesis of SLE.

Authors:  Aparna Mahajan; Martin Herrmann; Luis E Muñoz
Journal:  Front Immunol       Date:  2016-02-08       Impact factor: 7.561

8.  Presence of Anticardiolipin Antibodies in Patients with Dementia: A Systematic Review and Meta-Analysis.

Authors:  Md Asiful Islam; Fahmida Alam; Mohammad Amjad Kamal; Siew Hua Gan; Teguh Haryo Sasongko; Kah Keng Wong
Journal:  Front Aging Neurosci       Date:  2017-08-02       Impact factor: 5.750

Review 9.  Neurological and Neuropsychiatric Manifestations of Antiphospholipid-Antibody Syndrome (APS).

Authors:  Saba Asif; Anoushka Bali; Ashujot Kaur Dang; Daniel A Gonzalez; Rajeswar Kumar
Journal:  Cureus       Date:  2022-06-16

10.  Is it necessary to perform connective tissue disorders laboratory tests when a patient experiences the first demyelinating attack?

Authors:  Masoud Etemadifar; Alimohammad Fatemi; Hourossadat Hashemijazi; Amir Kazemizadeh
Journal:  J Res Med Sci       Date:  2013-07       Impact factor: 1.852

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.